SRZN — Surrozen, Inc./DE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1824893 ·
Last close
$22.21
Market Cap
$257.87M
52W High
$35.00
52W Low
$18.12
ADV30
233,090
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,000,000 | — | -10,456,000 | -127,505,000 | 120,709,000 | 106,910,000 | 398,856,000 |
| Dec 2025 | 528,000 | — | -12,639,000 | -183,159,000 | 98,726,000 | 89,245,000 | 286,488,000 |
| Sep 2025 | 983,000 | — | -10,885,000 | -71,643,000 | 94,046,000 | 81,335,000 | 117,561,000 |
| Jun 2025 | 983,000 | — | -9,017,000 | 39,746,000 | 102,696,000 | 90,390,000 | 55,582,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,244,000
Investing CF
$-128,000
Financing CF
$85,052,000
CapEx
$-128,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-527,285,000
Inventory
—
Receivables
$208,000
ST Investments
—
EBIT TTM
$-42,092,000
Pretax Income TTM
$-242,026,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,494,000
EBITDA
$-42,689,000
Free Cash Flow
$-26,107,124
Enterprise Value
$157,734,336
Total Cash
$106,910,000
Total Debt
$6,778,000
Shares Out
11,610,371
Trailing EPS
$-36.59
Book Value
$-24.21
ROE
—
ROA
-22.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,477,000 | -42,092,000 | -242,026,000 | 98,726,000 | 286,488,000 | — | -30,244,000 |
| Dec 2024 | 10,655,000 | -25,539,000 | -63,564,000 | 48,467,000 | 69,847,000 | — | -17,628,000 |
| Dec 2023 | 0 | -43,028,000 | -43,042,000 | 46,080,000 | 8,145,000 | — | -40,363,000 |
| Dec 2022 | 12,500,000 | -44,339,000 | -36,004,000 | 89,435,000 | 13,434,000 | — | -44,145,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.98
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVXL | ANAVEX LIFE SCIENCES CORP. | $254.85M | $2.75 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $269.24M | $1.08 | — |
| SABS | SAB Biotherapeutics, Inc. | $272.98M | $3.57 | — |
| FATE | FATE THERAPEUTICS INC | $285.57M | $2.45 | — |
| NMRA | Neumora Therapeutics, Inc. | $298.31M | $1.61 | — |
News headlines (Yahoo Finance, 1h cache)
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
2026-07-22 20:02 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conference
2026-07-15 20:05 · Yahoo
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
2026-05-17 14:17 · Yahoo
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:05 · Yahoo
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28 20:05 · Yahoo
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
2026-04-15 11:06 · Yahoo
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
2026-04-14 13:28 · Yahoo
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-23 20:05 · Yahoo
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
2026-02-15 14:10 · Yahoo
We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash Wisely
2025-12-08 13:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.